To further confirm that the KRAS mutant confers drug resistance via ALKBH5 SUMOylation in NSCLC cells, we inhibited ALKBH5 SUMOylation in both NCI-H522 and NCI-H23 cells by knocking down SUMO E2 UBC9. Here, ALKBH5 is linked to non-small cell lung carcinoma.